Target intelligence / Profile preview

Ubiquitin-specific peptidase 4 (USP4)

Target
USP4
Molecular classification
Enzyme, Cysteine protease (family C19), Deubiquitinating enzyme, Hydrolase
01

Overview

Ubiquitin-specific peptidase 4 (USP4) is a multidomain cysteine protease within the deubiquitinating enzyme (DUB) family, responsible for removing monoubiquitinated and polyubiquitinated chains (such as K48 and K63 linkages) from substrate proteins. USP4 regulates several critical cellular processes, including signal transduction (in the NF-κB, TGF-β, and Wnt/β-catenin pathways), spliceosome activity, DNA repair via homologous recombination, and cell fate determination. It shuttles between the cytoplasm and nucleus and is tightly regulated by post-translational modifications (such as phosphorylation and ubiquitination). Aberrant USP4 expression or mutation is linked to the progression and poor prognosis of various cancers and immune disorders. Efforts are ongoing to develop selective USP4 inhibitors as novel therapeutics for cancer and inflammatory diseases[1][3][4][5][6][7].

Other names
USP4Ubiquitin specific protease 4UNPUnphubiquitin carboxyl-terminal hydrolase 4
02

Mechanism of action

Inhibition leads to increased ubiquitination and degradation of signaling proteins (e.g., BRCA1, TGF-β receptor, NF-κB pathway components), modulating cell survival, proliferation, and immune signaling[1][3][7].

03

Biological functions

Deubiquitination of protein substratesSignal transductionPre-mRNA splicing regulationDNA repair (homologous recombination, double-strand break repair)Cell cycle regulationCell growth and differentiationApoptosisImmune response modulation
04

Disease associations

Cancer (breast, others)InflammationImmune-related disordersNeurodegenerative disease (potential implication)Other (embryonic development, cell fate decisions)
05

Safety considerations

Potential safety risks include impacts on global ubiquitin homeostasis, off-target effects, disturbance of essential cell cycle, DNA repair, and immune pathways.Targeting USP4 may lead to undesirable effects on normal cell proliferation and immune function
06

Interacting drugs

No FDA-approved drugs currently, but inhibitors/chemical probes targeting USP4 are under investigation for cancer and inflammation
07

Biomarkers

Overexpression or methylation status of USP4 in tumor tissue may serve as a biomarker for cancer diagnosis, prognosis, or treatment response

Beyond the preview

Go deeper on Ubiquitin-specific peptidase 4 (USP4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitin-specific peptidase 4 (USP4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call